US2008131889A1PendingUtilityA1

Novel human genes and gene expression products: II

61
Assignee: MAYO MEDICAL VENTURESPriority: Aug 31, 1998Filed: Apr 30, 2007Published: Jun 5, 2008
Est. expiryAug 31, 2018(expired)· nominal 20-yr term from priority
C12Q 2600/136A61P 43/00C07K 14/47C12Q 2600/158A01K 2217/05A61P 35/00C12Q 1/6886G01N 33/57535
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly in colon cancer tissue.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . A method of determining the phenotype of a cell, comprising detecting the differential expression, relative to a normal cell, of at least one nucleic acid sequence of SEQ ID Nos. 1, 3, 5, or 7, wherein the nucleic acid is differentially expressed by at least 0.5 fold. 
     
     
         15 . A method for determining the phenotype of cells in a sample from a patient, comprising:
 (a) providing a nucleic acid probe comprising a nucleotide sequence having at least 8 consecutive nucleotides of any of SEQ ID Nos. 1, 3, 5, or 7, or a sequence complementary thereto;   (b) providing a first sample from a patient, wherein the first sample contains cells suspected of being cancerous;   (c) providing a second sample from the patient containing cells which are substantially non-cancerous;   (d) contacting the nucleic acid probe under stringent conditions with each of said first and second samples; and   (e) comparing (a) the amount of hybridization of the probe with mRNA of the first cell sample, with (b) the amount of hybridization of the probe with mRNA of the second cell sample, wherein a difference of at least about 0.5 fold in the amount of hybridization with the mRNA of the first sample as compared to the amount of hybridization with the mRNA of the second sample is indicative of the phenotype of cells in the first sample.   
     
     
         16 . A method of determining the phenotype of a cell comprising detecting the differential expression, relative to a normal cell, of at least one protein encoded by a nucleic acid comprising one of SEQ ID Nos. 1, 3, 5, or 7, or a sequence complementary thereto, wherein the protein is differentially expressed by at least about 0.5 fold. 
     
     
         17 . The method of  claim 16  wherein said differential expression of said protein is detected in an immunoassay. 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . A method for detecting cancer in a patient sample comprising contacting an antibody to a polypeptide having an amino acid sequence comprising at least a portion of one or more of SEQ ID Nos. 2, 4, 6, or 8 with the sample and detecting the reaction of the antibody with the polypeptide, wherein the presence or amount of the polypeptide detected is indicative of the presence of cancer. 
     
     
         24 . The method of  claim 23  wherein the cancer is colon cancer.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.